A specialty pharma company received a Complete Response Letter (CRL) from FDA for its NDA for a novel pain medication. The CRL cites three deficiencies: a CMC manufacturing process concern, a safety signal requiring additional post-market commitment data, and a labeling dispute over the indication.
